Question explored with the scientific record
how safe is keytruda immunotherapy?
The short version: Keytruda is a powerful immune disinhibitor that trades a real risk of severe, sometimes fatal, autoimmune attack for a chance at tumor control. The evidence here is a collection of case reports and trial summaries, not a single head-to-head safety trial against no treatment.
The evidence you retrieved is almost entirely case reports [1-8, 10, 11, 18] and narrative reviews [16, 17]. These document that Keytruda can trigger a wide range of immune-related adverse events (irAEs): pneumonitis in about 3.6% of lung cancer patients (grade 3-4 in 1.1%) [13], myasthenia gravis that can be fatal [2, 7], myocarditis [1], Guillain-Barré-like neuropathy [8], fulminant type 1 diabetes [10], and cholangiopathy [18]. The largest single-center retrospective study here found 12.8% of 648 patients had serious (grade 3-4) irAEs [15]. The KEYNOTE-001 trial reported a 3.8% rate of any-grade pneumonitis, with 2% being grade 3-5 [12]. The meta-analysis confirms PD-1 inhibitors cause more pneumonitis than PD-L1 inhibitors [13]. The evidence does not include a single randomized trial comparing Keytruda to a true placebo (no active treatment) with long-term all-cause mortality as the primary endpoint. The trials cited compare Keytruda to chemotherapy or other active drugs, which obscures the absolute harm of the drug itself.
| Adverse Event (from evidence) | Incidence in studied populations | Severity |
|---|---|---|
| Any-grade irAE (NSCLC trials) | ~25% [17] | Mostly manageable |
| Grade 3-5 irAE (retrospective, 648 patients) | 12.8% [15] | Requires hospitalization, often steroids |
| Pneumonitis (PD-1, meta-analysis) | 3.6% all-grade; 1.1% grade 3-4 [13] | Can be fatal; 7 deaths in meta-analysis [13] |
| Myasthenia gravis (case series) | Rare, but documented fatal cases [2, 7] | Fatal in ~30% of reported cases [7] |
| Treatment discontinuation (age ≥80) | 16.1% [17] | Loss of cancer therapy |
The mechanism is straightforward: Keytruda blocks PD-1, a brake on the immune system. This releases T cells to attack tumors, but it also releases them to attack healthy tissue. The evidence shows this is not a rare fluke; it is the drug's core action. The question is whether the benefit (tumor shrinkage, extended life in some cancers) outweighs the risk of permanent organ damage or death for a specific patient. That is a deeply individual calculation, not a population average. The evidence here does not provide a clean answer for any single person.
My call: Keytruda is not "safe" in any ordinary sense of the word. It is a high-risk, high-reward intervention with a well-documented and serious toxicity profile that must be weighed against the specific cancer and the patient's own physiology. Confidence: high.
Sources examined 18
-
Severe ophthalmoplegia and myocarditis following the administration of pembrolizumab
This study reports a rare case of severe ophthalmoplegia and myocarditis in a 79-year-old man with metastatic gastric cancer following the administration of pembrolizumab, highlighting the importance of early recognition and management of immune-related adverse events.
DOI: 10.1016/j.ejca.2017.11.026 -
Pembrolizumab-induced myasthenia gravis: A fatal case report
This case report details a fatal instance of myasthenia gravis induced by pembrolizumab in a 63-year-old male with no prior history of the condition, highlighting the potential severe immune-related adverse events associated with this cancer therapy.
DOI: 10.1177/1078155216687389 -
Bullous pemphigoid, an autoantibody-mediated disease, is a novel immune-related adverse event in patients treated with anti-programmed cell death 1 antibodies
This study reports three cases of bullous pemphigoid, an autoantibody-mediated disease, occurring in patients with metastatic melanoma treated with anti-PD1 antibodies, highlighting the need for awareness of this potential immune-related adverse event.
DOI: 10.1097/CMR.0000000000000260 -
Pembrolizumab-induced acute thrombosis
This case report presents two patients with non-small cell lung cancer who developed acute thrombosis as an immune-related adverse event following pembrolizumab treatment, highlighting the need for awareness and management of such rare but serious complications.
DOI: 10.1097/MD.0000000000010772 -
Pembrolizumab-induced Pneumonitis
Case report of pembrolizumab-induced pneumonitis in a 47-year-old woman with triple-negative breast cancer, showing rapid respiratory decline requiring intubation and full recovery after short-term high-dose prednisone, underscoring a rare but treatable immune-related adverse ev…
DOI: 10.46570/utjms.vol11-2023-774 -
Pulmonary nodules and immunotherapy: disease progression or toxicity of anti-PD1/anti-PDL1 checkpoint inhibitors?
This study reports two cases of patients treated with pembrolizumab who developed pulmonary immune-related adverse events that mimicked metastasis, highlighting the diagnostic challenges and the need for careful evaluation in immunotherapy-related lung toxicity.
DOI: 10.1016/j.ejca.2017.12.013 -
Myasthenia gravis: An emerging toxicity of immune checkpoint inhibitors
This study reviews the emerging toxicity of myasthenia gravis associated with immune checkpoint inhibitors, highlighting its clinical presentations, management strategies, and significant mortality rates.
DOI: 10.1016/j.ejca.2017.05.041 -
Pembrolizumab-Induced Severe Neuropathy in a Patient with Metastatic Urothelial Carcinoma after Achieving Complete Response: Guillain-Barré Syndrome-Like Onset
This case report describes pembrolizumab-induced severe neuropathy with a Guillain-Barré syndrome-like onset in an elderly woman with metastatic urothelial carcinoma, its management with high-dose corticosteroids, and the observation that a complete tumor response was maintained…
DOI: 10.1159/000511567 -
Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients
This study investigates the predictive and prognostic roles of immune-related adverse events (irAEs) in patients with non-small-cell lung cancer (NSCLC) treated with anti-PD-1 immunotherapy, finding that the occurrence of irAEs is associated with improved overall response rates,…
DOI: 10.1016/j.cllc.2019.02.006 -
Continued administration of pembrolizumab for adenocarcinoma of the lung after the onset of fulminant type 1 diabetes mellitus as an immune‐related adverse effect: A case report
A case report of a 61-year-old woman with advanced NSCLC who developed fulminant type 1 diabetes mellitus and thyroiditis as immune-related adverse events during pembrolizumab therapy, yet continued pembrolizumab for 21 cycles with insulin and thyroid hormone replacement and ach…
DOI: 10.1111/1759-7714.13065 -
Progressive multifocal leukoencephalopathy in systemic lupus erythematosus managed with pembrolizumab: A case report with literature review
PD-1 blockade with pembrolizumab produced a delayed but meaningful clinical and virologic improvement in a patient with systemic lupus erythematosus–associated PML, without triggering an SLE flare, suggesting checkpoint inhibitors may be a plausible therapeutic option in PML wit…
DOI: meta/10.1177/09612033211035443 -
459P Risk of pneumonitis in patients with advanced NSCLC treated with pembrolizumab in KEYNOTE-001
This study investigates the incidence and management of pneumonitis in patients with advanced non-small cell lung cancer (NSCLC) treated with pembrolizumab in the KEYNOTE-001 trial, finding a low incidence of pneumonitis and effective management strategies.
DOI: 10.1093/annonc/mdv532.43 -
Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer
A comprehensive systematic review and meta-analysis comparing pneumonitis incidence in NSCLC patients treated with PD-1 versus PD-L1 inhibitors, finding higher pneumonitis with PD-1 inhibitors (all grades 3.6% vs 1.3%; grade 3–4 1.1% vs 0.4%), and higher risk in treatment-naïve …
DOI: 10.1016/j.chest.2017.04.177 -
Management of side effects of immune checkpoint blockade by anti‐CTLA‐4 and anti‐PD‐1 antibodies in metastatic melanoma
An overview of immune checkpoint inhibitors (CTLA-4 and PD-1 antibodies) in metastatic melanoma, detailing the spectrum, incidence, and management of immune-related adverse events across major trials, their organ-specific toxicities, and the relationship between toxicity and tre…
DOI: 10.1111/ddg.13047 -
Immune-Mediated Adverse Effects of Checkpoint Inhibitors: A Clinical Experience
A retrospective single-center study at Masaryk Memorial Cancer Institute analyzing immune checkpoint inhibitor–associated immune-related adverse events (irAEs) in 648 cancer patients treated between 2011 and 2020, detailing frequencies, severities, management, and including a cl…
DOI: 10.2478/afpuc-2022-0006 -
Immune-mediated respiratory adverse events of checkpoint inhibitors
This is a narrative review of immune-mediated pneumonitis (IMP) associated with immune checkpoint inhibitors (ICIs), summarizing its pathophysiology, incidence, diagnosis, and management, and emphasizing that pneumonitis occurs in up to ~5% of patients, is more common with anti-…
DOI: 10.1097/cco.0000000000000291 -
Impact of Immunosenescence on Immune‐Related Adverse Events in Elderly Patients With Cancer
This review examines the impact of immunosenescence on immune-related adverse events in elderly cancer patients, summarizing inconsistent evidence on irAE incidence and highlighting potential mechanisms and the need for geriatric assessment.
DOI: 10.1002/agm2.70000 -
Pembrolizumab as a Cause of Cholangiopathy in a Patient With Metastatic Melanoma
This case study describes a 63-year-old woman who developed cholangiopathy after treatment with pembrolizumab for metastatic melanoma, highlighting the potential immune-mediated liver injury associated with PD-1 inhibitors.
DOI: 10.1002/hep.31089